Associated Papers
Evolution and long-term outcomes of combined immunodeficiency due to CARMIL2 deficiency.
Kolukisa B et al.
Allergy, 2022
Case report: Primary immunodeficiency due to a novel mutation in CARMIL2 and its response to combined immunomodulatory therapy.
Zhu Y et al.
Frontiers in Pediatrics, 2022
36727012 (PubMed )
Supplement: Datasheet3.pdf
Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation.
Shamriz O et al.
Clinical and Experimental Immunology, 2020
Select a paper to view details